IL270693A - Glucuronide prodrugs of janus kinase inhibitors - Google Patents

Glucuronide prodrugs of janus kinase inhibitors

Info

Publication number
IL270693A
IL270693A IL270693A IL27069319A IL270693A IL 270693 A IL270693 A IL 270693A IL 270693 A IL270693 A IL 270693A IL 27069319 A IL27069319 A IL 27069319A IL 270693 A IL270693 A IL 270693A
Authority
IL
Israel
Prior art keywords
inhibitors
janus kinase
glucuronide drug
kinase inhibitors
glucuronide
Prior art date
Application number
IL270693A
Other languages
English (en)
Hebrew (he)
Original Assignee
Theravance Biopharma R& D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R& D Ip Llc filed Critical Theravance Biopharma R& D Ip Llc
Publication of IL270693A publication Critical patent/IL270693A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
IL270693A 2017-05-23 2019-11-17 Glucuronide prodrugs of janus kinase inhibitors IL270693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509847P 2017-05-23 2017-05-23
PCT/US2018/033818 WO2018217700A1 (en) 2017-05-23 2018-05-22 Glucuronide prodrugs of janus kinase inhibitors

Publications (1)

Publication Number Publication Date
IL270693A true IL270693A (en) 2020-01-30

Family

ID=62621001

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270693A IL270693A (en) 2017-05-23 2019-11-17 Glucuronide prodrugs of janus kinase inhibitors

Country Status (14)

Country Link
US (2) US10745405B2 (enExample)
EP (1) EP3609899A1 (enExample)
JP (1) JP2020520955A (enExample)
KR (1) KR20200010440A (enExample)
CN (1) CN110662747A (enExample)
AU (1) AU2018273866B2 (enExample)
BR (1) BR112019024509A2 (enExample)
CA (1) CA3063963A1 (enExample)
IL (1) IL270693A (enExample)
MX (1) MX2019014054A (enExample)
NZ (1) NZ759764A (enExample)
PH (1) PH12019502605A1 (enExample)
RU (1) RU2019142472A (enExample)
WO (1) WO2018217700A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
CN111196831B (zh) * 2020-01-20 2023-05-09 山西医科大学 一种呋喃酚葡萄糖醛酸结合物的制备方法
MX2023009178A (es) 2021-02-15 2023-08-21 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
AU2022328282A1 (en) * 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
CN119923257A (zh) * 2022-04-15 2025-05-02 密歇根大学董事会 Jak抑制剂类似物、制剂及其用途
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
EP4637724A1 (en) 2022-12-22 2025-10-29 KRKA, d.d., Novo mesto Veterinary composition comprising oclacitinib
WO2024148049A1 (en) * 2023-01-04 2024-07-11 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) * 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
US7798257B2 (en) 2004-04-30 2010-09-21 Smith International, Inc. Shaped cutter surface
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
EP2695617B1 (en) 2009-12-23 2019-01-09 Glycomyr Inc. Vitamin D glycosides and sulfates for treating intestinal diseases
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
AU2011213198B2 (en) 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
US20140357557A1 (en) 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
CA3003283A1 (en) 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
CN106496233B (zh) * 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
MX2019014054A (es) 2020-02-05
US10745405B2 (en) 2020-08-18
BR112019024509A2 (pt) 2020-06-23
EP3609899A1 (en) 2020-02-19
JP2020520955A (ja) 2020-07-16
KR20200010440A (ko) 2020-01-30
CA3063963A1 (en) 2018-11-29
WO2018217700A1 (en) 2018-11-29
US20180339990A1 (en) 2018-11-29
US20210032250A1 (en) 2021-02-04
PH12019502605A1 (en) 2020-10-26
NZ759764A (en) 2022-07-01
AU2018273866B2 (en) 2021-09-30
RU2019142472A3 (enExample) 2021-09-23
CN110662747A (zh) 2020-01-07
AU2018273866A1 (en) 2019-12-19
RU2019142472A (ru) 2021-06-24

Similar Documents

Publication Publication Date Title
IL282801A (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
EP3873477A4 (en) CYCLIN DEPENDENT KINASE 7 (CDK7) INHIBITOR
MA50205A (fr) Formulation de nicotine
EP3668839A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
HUE060078T2 (hu) CDK7 gátlására alkalmas vegyületek
MA51616A (fr) Inhibiteurs d'adn-pk
EP3740207A4 (en) CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3740206A4 (en) INHIBITORS OF THE CYCLINE-DEPENDENT KINASE 7 (CDK7)
DK3290418T3 (da) Janus Kinase (JAK)-hæmmere
HUE050842T2 (hu) Janus-kináz inhibitor
EP3651768A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
DK3265084T3 (da) Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EP3826775A4 (en) ATOMIZER
EP3405192A4 (en) BRUTON TYROSINE KINASE HEMMER
EP3250367A4 (en) ACTIVE CALIBRATION
EP3804707A4 (en) KINASE INHIBITOR
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA49006A (fr) Inhibiteurs d'ip6k
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
IL267829B (en) History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use
EP3765008A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE